VYNE Therapeutics to Join Leerink Partners Therapeutics Forum on I&I and Metabolic Diseases

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, is focusing on innovative therapies for immuno-inflammatory conditions. The company announced that its management team will engage in one-on-one meetings at the Leerink Partners Therapeutics Forum on Immunology and Inflammation (I&I) and Metabolic Diseases, scheduled for July 9, 2024.

The core mission of VYNE Therapeutics is to enhance patient lives through the development of proprietary, innovative, and differentiated treatments specifically targeting immuno-inflammatory diseases. This mission is exemplified by the company’s unique bromodomain & extra-terminal (BET) domain inhibitors found in its InhiBET™ platform. The platform includes two key product candidates: VYN201, a locally administered pan-BD BET inhibitor, and VYN202, an orally available BD2-selective BET inhibitor. Both of these inhibitors were licensed from Tay Therapeutics Limited, showcasing VYNE's commitment to leveraging unique scientific advancements.

VYNE Therapeutics' focus on immuno-inflammatory conditions places it in a strategic position within the biopharmaceutical industry. The company’s innovative approach through the InhiBET™ platform aims to address unmet medical needs, providing new treatment options for patients. The participation of VYNE's management in the Leerink Partners Therapeutics Forum indicates a proactive approach to engaging with industry peers, investors, and stakeholders, fostering collaboration and potential partnerships.

The Leerink Partners Therapeutics Forum is a significant event that brings together leaders in the field of immunology, inflammation, and metabolic diseases. VYNE's involvement in this forum underscores the company's active role in the biopharmaceutical community and its commitment to advancing its therapeutic candidates through strategic discussions and collaborations.

In summary, VYNE Therapeutics Inc. continues to forge ahead in the development of specialized therapies for immuno-inflammatory conditions. With its proprietary BET domain inhibitors and participation in key industry forums, the company is poised to make significant contributions to the field of biopharmaceuticals.